Peptide Therapy Foundations

The largest section, and the widest gap between a plausible mechanism and a proven result. Twelve compounds for tissue repair, recovery, and gut-barrier integrity, each run through mechanism, then evidence tier, then regulatory status. You leave able to rank a compound by the actual weight of its evidence.

Rather than administering growth hormone, these compounds prompt the body to release its own, preserving its natural rhythm and feedback loop. Ten of them, separated by receptor target, potency, appetite effect, and cortisol profile. You leave able to match a compound to a clinical goal rather than to the best-known name.

Cognitive decline is the concern patients raise most and clinicians can least afford to answer loosely. Nine compounds active in the central nervous system, spanning human trial data to preclinical-only, each framed as one part of a broader strategy. Includes what to do when a foundational mechanism paper has been retracted.

The category patients arrive already asking about. Six agents, from the gut-hormone class that reshaped weight management through its dual and triple-target successors, compared on weight, glycemic, cardiovascular, kidney and liver-fat evidence. You leave able to tell them apart on pharmacology rather than brand familiarity.

Skin is where patients can see results, so claims run furthest ahead of the evidence. Six peptides across expression lines, collagen support, and pigment signaling, compared against the injectables and topicals patients already know. You leave able to build combinations and set expectations that hold up.

Patients ask for immune support meaning they want it stronger. These five compounds rebalance immune signaling instead, and several are approved in dozens of countries but not here. You leave able to separate a real mechanism from a marketing claim, and to tell apart compounds that are routinely confused with one another.

The body clock sets hormone release, immune activity, and cellular repair on a daily schedule, and drift shows up throughout the body. Covers the peptides that touch that clock, the limited human evidence behind them, and why compounds influencing cellular lifespan warrant care in patients with a malignancy history.

Mitochondria produce the energy every cell runs on, and their decline underlies much of what patients describe as fatigue. Three peptides at three very different levels of proof: one with no clinical trials, one with human observational data, one FDA-approved. You leave able to explain why compounds shelved together deserve very different confidence.

Sleep is where patients notice decline first, and where the peptide conversation gets least rigorous. Three compounds studied for sleep and nighttime physiology, on evidence that is often thin, dated, or traceable to a single institute. The section says so plainly, so you can hold a sleep conversation that doesn't overpromise.